Dr. Füst György irodalomjegyzéke (1968-2010) Impakt faktorral rendelkező, külföldön kiadott nemzetközi folyóiratokban megjelent tudományos közlemények jegyzéke
1. M.J. Surján, G. Füst.: The control of cardiolipin and lecithin products with the 50 % hemolysis
method. Z. Immun.-Forsch. 1346, 303, 1968. (impakt faktor: 1,576)
2. G. Füst, G. Fóris: Newer data on the role of complement system in toxicity of endotoxin.
Experientia, 26, 1362, 1970. (impakt faktor: 1,580)
3. M. Surján, G. Füst, I. Balogh: Suphydryl sensivity of syphilitic antibodies and temperature
dependence in complement fixation. Brit. J. Ven. Dis. 47, 87, 1971. (impakt faktor: 0,456)
4. G. Füst, S. Kósa: Antigenic relationship between the C4 inactivating substance produced by
KB cell cultures and the first component of human complement (C1). Med. Microbiol. Immunol. 157, 244, 1972. (impakt faktor: 1,082)
5. M. Surján, G. Füst: National Standard for human syphilitic serum and the use of International
Unit in the routine work of syphilis serology. J. Biol. Standardization 1, 81, 1973. (impakt faktor: 0,872)
6. G. Füst, G. Fóris: Role of complement system in the endotoxicity-enhancing and endotoxin-
detoxifying effect of serum. Med Microbiol. Immunol. 159, 141, 1974. (impakt faktor: 1,082)
7. G. Füst, Gy. Petrás, E. Ujhelyi: Activation of the complement system during infections due to
Gram-negative bacteria. Clin. Immunol. Immunopathol. 5, 293, 1976. (impakt faktor: 2,352)
8. G. Füst, A. Erdei, G. Sármay, G.A. Medgyesi, J. Gergely: Functionally active C1 on the surface
of human peripheral lymphocytes: Its role in the complement-mediated inhibition of the Fc receptor of B lymphocytes. Clin. Immunol. Immunopathol. 5, 377, 1976. (impakt faktor: 2,352)
9. G. Füst, M. Cécsi-Nagy, G.A. Medgyesi, J. Kulics, J. Gergely: Study of the interaction between
monoclonal IgM proteins and the complement system. Immunochemistry, 13, 793, 1976. (impakt faktor: 1,946)
10. G. Füst, L. Bertók, S. Juhász-Nagy: Interactions of radiodetoxified Escheria coli endotoxin
preparations with the complement system. Infect. Immunity 16, 26, 1977. (impakt faktor: 1,082)
11. A. Erdei, G. Füst, G. Sármay, G.A. Medgyesi, J. Gergely: Studies on the mechanism of the
complement-mediated inhibition of the Fc and C3 receptors of B lymphocytes. Clin. Immunol. Immunopathol. 8, 367, 1977. (impakt faktor: 2,352)
12. G. Füst, G.A. Medgyesi, F. Franek: Complement consumption by immune complexes
containing various pig anti-DNP antibodies and DNP-serum albumin. Immunochemistry, 14, 259, 1977. (impakt faktor: 1,946)
13. G. Füst, J. Székely, S. Gerő: Circulating immune complexes in vascular diseases. Lancet 1,
193, 1977. (impakt faktor: 15,871)
14. G.A. Medgyesi, G. Füst, J. Gergely, H. Bazin: Classes and subclasses of rat
immunoglobulins: Interaction with the complement system and with staphylococcal protein A. Immunochemistry 15, 125, 1978. (impakt faktor: 1,946)
15. G. Füst, É. Szondy, J., Székely, I. Nánai, S. Gerő: Studies on the occurrence of circulating
immune complexes in vascular diseases. Atherosclerosis 29, 181, 1978. (impakt faktor: 2,462)
16. J. Gergely, G. Füst, É. Rajnavölgyi, G.A. Medgyesi: The influence of immune complex
composition on the triggering of the complement dependent complex elimination. Panminerva med. 20, 1, 1978. (impakt faktor: 0,131)
17. G. Füst, G.A. Medgyesi, M. Csécsi-Nagy, É. Rajnavölgyi, J. Gergely: Factors influencing the
in vitro interaction between immunoglobulins and isolated C1: a critical study. Immunology 34, 869, 1978. (impakt faktor: 2,952)
18. G.Gy. Petrányi, Gy. Györffy, M. Benczur, M. Varga, É. Gyódi, K. Ónody, Gy. Füst, I. Láng:
Features genetics and in vivo importance of lymphocyte mediated natural cytotoxicity. Panminerva med. 20, 71, 1978. (impakt faktor: 0,131)
19. É. Rajnavölgyi, G. Füst, J. Ember, G.A. Medgyesi, J. Gergely: Evidences proving the
intercalation hypothesis of the C-mediated complex release activity (CRA). Immuno- chemistry 15, 335, 1978. (impakt faktor: 1,946)
20. M. Sándor, G. Füst, G.A. Medgyesi, J. Gergely: Isolation and characterization of Fc-receptors
shed from human peripheral mononuclear cells. Immunology 35, 559, 1978. (impakt faktor: 2,952)
21. É. Szondy, M. Horváth, G. Füst, E. Ling, J. Fehér, S. Gerő: The effect of clofibrate and
pyridinol carbamate on the circulating immune complexes and cellular immune response in experimental atherosclerosis. Atherosclerosis. 31, 251, 1978. (impakt faktor: 2,462)
22. G. Füst, .A. Medgyesi, É. Rajnavölgyi, M. Csécsi-Nagy, K. Czikora, J. Gergely: Possible
mechanisms of the first step of the classical complement activation pathway: binding and activation of C1. Immunology 35, 873, 1978. (impakt faktor: 2,942)
23. É. Rajnavölgyi, G. Füst, J. Kulics, J. Ember, G.A. Medgyesi, J. Gergely: The effect of immune
complex composition on complement activation and complement dependent complex release. Immunochemistry, 15, 887, 1978. (impakt faktor: 1,946)
24. F. Franek, M.A. Saber, J. Doskocil, J. Novotny, Gy. Füst: Non-antibody components in
porcine anti-DNP antibody preparations obtained by affinity chromatography. Molec. Im- munol. 16, 389, 1979. (impakt faktor: 1,946)
25. G. Füst, J.L. Molenear: Inhibition by nascent C3b of the immune complex binding to
lymphocytes. Immunology Letts. 1, 61, 1979. (impakt faktor: 1,513)
26. M. Sándor, G. Füst, G.A. Medgyesi, A. Erdei, J. Gergely: The heterogeneity of Fc receptors
on human peripheral mononuclear blood cells. Immunology 38, 553, 1979. (impakt faktor: 2,952)
27. G.A. Medgyesi, G. Füst, J. Gergely, J.-C. Jaton: Activation of the classical complement
pathway by homogeneous anti-SIII antibody bound to bivalent or trivalent oligosaccharide antigens. Molec. Immunol. 16, 949, 1979. (impakt faktor: 1,946)
28. A. Erdei, G. Füst, G.A. Medgyesi, J. Gergely: Complement-dependent inhibition of Fc
receptors on human peripheral blood mononuclear cells: inhibition of the binding of aggregated IgG, soluble and particulate immune complexes. Immunology Letts. 1, --224, 1980. (impakt faktor: 1,513)
29. G. Füst, G.A. Medgyesi, H. Bazin, J. Gergely: Differences in the ability of rat IgG subclasses
to consume complement in homologous and heterologous serum. Immunology Letts. 1, 249, 1980. (impakt faktor: 1,513)
30. A. Mód, G. Füst, S.R. Hollán: Presence of C1 in immune complexes precipitated from sera of
leukaemic patients by polyethylene glycol. Immunology Letts. 2, 91, 1980.
31. M. Sándor, L.I. Horváth, Cs. Bagyinka, A. Erdei, G. Füst, J. Gergely: Effect of binding of C3
and its fragments on the plasma membrane fluidity of lymphocyte. Immunology Letts. 2, 115, 1980. (impakt faktor: 1,513)
32. A. Mód, G. Füst, E. Puskás, S.R. Hollán: Circulating immune complexes and phagocytosis in
acute leukaemia. Clin. lab. Haemat. 2, 293, 1980. (impakt faktor: 0,469)
33. G. Füst, M. Kávai, Gy. Szegedi, K. Merétey, A. Falus, Á. Lenkey, M. Misz: Evaluation of
different methods for detecting circulating immune complexes. An inter-laboratory study. J. Immunol. Methods 38, 281, 1980. (impakt faktor: 1,837)
34. G.A. Medgyesi, K. Miklós, J. Kulics, G. Füst, J. Gergely, H. Bazin: Classes and subclasses of
rat antibodies: reaction with the antigen and interaction of the complex with the complement system. Immunology 43, 171, 1981. (impakt faktor: 2,952)
35. É. Szondy, Zs. Mezei, J. Székely, G. Füst, S. Gerő: Serial measurement of circulating
immune complexes in patients with myocardial infarction. Brit. Heart J. 46, 93, 1981. (impakt faktor: 1,792)
36. L. van Es, S.J. Smith, P.H. Schur, G. Hauptmann, W. Leskovar, P. Spath, G. Füst, P.
Lachmann, U. Lother, R.A. Thomson, T.B.L. Kirkwood: International collaborative study of four candidate reference preparations for the antigenic and haemolytic measurement of
human serum complement components. J. Biol. Standardization 9, 91, 1981. (impakt faktor: 0,416)
37. A. Mód, G. Füst, J. Gergely, S.R. Hollán, M.P. Dierich: Alpha-1-antitrypsin-induced inhibition
of complement-dependent phagocytosis. Immunobiology 158, 338, 1981. (impakt faktor: 1,576)
38. Kávai, M., M. Sándor, Gy. Szegedi, G. Füst, J. Gergely: Effect of soluble immune complexes
on Fc and C3 receptor-dependent phagocytosis by human monocytes. Immunology 44, 599, 1981. (impakt faktor: 2,952)
39. G. Füst, B. Fekete, I. Angyal, Á. Jakab, A. Pál, K. Merétey, A. Falus, K. Török, Gy. Szegedi,
M. Kávai, É. Puskás, M. Csécsi-Nagy, T. Szabó, Á. Lenkey, M. Misz: Evaluation of different methods for detecting circulating immune complexes. Studies in patients with lung cancer. J. Immunol. Methods, 46, 259, 1981. (impakt faktor: 1,837)
40. K. Miklós, J. Kulics, F. Franek, G. Füst, J. Gergely: Complement-mediated fragmentation of
soluble and insoluble immune complexes containing porcine anti-DNP antibodies. Mol. Immunol. 19, 307, 1982. (impakt faktor: 1,946)
41. A.I. Farkas, G.A. Medgyesi, G.Füst, K. Miklós, J. Gergely: Immunogenicity of antigen
complexed with antibody I. Role of different isotypes. Immunology 45, 483, 1982. (impakt faktor: 2,952)
42. É. Puskás, G. Füst, I. Angyal, N. Chi-Phi, J. Gergely: Serial measurement of circulating
immune complexes in healthy subjects. Immunol. Letts. 4, 223, 1982. (impakt faktor: 1,513)
43. A. Dobozy, G. Füst, A.Sz. Kenderessy, J. Hunyadi, Zs. Fábry, N. Simon: Inhibitory effect of
C3b on rosette formation of peripheral blood mononuclear cells with mouse erythrocytes. Clin.exp. Immunol. 49, 230, 1982. (impakt faktor: 2,142)
44. A. Mód, G. Füst, S.R. Hollán: Characterization of circulating immune complexes by
nephelometry in acute leukaemia. Clin. Lab. Haematol. 4, 139, 1982. (impakt faktor: 0,469)
45. Do quang Minh, E. Czink, A. Mód, G. Füst, S.R. Hollán: Serial complement measurements in
patients with leukaemia. Clin. lab. Haematol. 5, 23, 1983. (impakt faktor: 0,469)
46. G. Fóris, B. Dezső, G.A. Medgyesi, G. Füst: Effect of angiotensin II on macrophage functions.
Immunology 48, 529, 1983. (impakt faktor: 2,952)
47. G. Fóris, G. Füst, G.A. Medgyesi: The effect of oligopeptides on the C3b receptor-mediated
functions of rat macrophages. Immunol. Letts. 6, 7, 1983. (impakt faktor: 1,513)
48. B. Fekete, Gy. Füst, A. Pál, I. Angyal, Á. Jakab, K. Merétey, A. Falus, K. Török, Gy. Szegedi,
M. Kávai, É. Puskás, M. Csécsi-Nagy, T. Szabó, Á. Lenkey, M. Misz: Clinical correlates of circulating immune complex levels in advanced lung cancer. Oncology 40, 106, 1983. (impakt faktor: 1,156)
49. Do quang Minh, E. Czink, G. Füst, S.R. Hollán: Acquired C1-esterase inhibitor deficiency and
recurrent herpes infection in a patient with chronic lymphocytic leukaemia. Diagn. Immunol. 1, 68, 1983. (impakt faktor: 0,844)
50. A. Erdei, G. Füst, J. Gyenes, Zs. Fábry, J. Gergely: C3b acceptors on human peripheral
blood mononuclear cells: characterization and functional role. Immunology 49, 423, 1983. (impakt faktor: 2,952)
51. E. Koó, K.G. Fehér, T. Fehér, G. Füst: Effect of dehydroepiandrosterone on hereditary
angioedema. Klin Wochenschr. 61, 715, 1983. (impakt faktor: 0,857)
52. J. Kulics, E. Rajnavölgyi, G.Füst, J. Gergely: Interaction of C3 and C3b with immunoglobulin
G. Mol. Immunol. 20, 805, 1983. (impakt faktor: 1,946)
53. N. Anh-Tuan, A. Falus, G. Füst, K. Merétey, G.A. Medgyesi, S.R. Hollán: Precipitability and
composition of HBsAg-anti-HBs immune complexes formed in the presence of complement. A model of circulating immune complex analysis. J. Immunol. Methods 64, 283, 1983. (impakt faktor: 1,837)
54. É. Szondy, M. Horváth, Zs. mezey, J. Székely, É. Lengyel, G. Füst, S. Gerő: Free and
complexed anti-lipoprotein antibodies in vascular diseases. Atherosclerosis 49, 69, 1983. (impakt faktor: 2,462)
55. N. Anh-Tuan, F.D. Tóth, B. Szabó, J. Kiss, A. Réthy, A. Falus, K. Merétey, A. Mód, G. Füst, L.
Váczi, S.R. Hollán: Antibodies to primate retrovírus antigens in circulating immune complexes of patients with acute myeloid leukaemia. Leukemia Res. 8, 863, 1984. (impakt faktor: 1,293)
56. N. Anh-Tuan, A. Falus, G. Füst, K. Merétey, S.R. Hollán: Appearance of covalently bound
antigen in immune complexes formed during the activation of complement. J. Immunol. Methods 75, 257, 1984. (impakt faktor: 1,837)
57. É. Szondy, É. Lengyel, Zs. Mezey, G. Füst, S. Gerő: Occurrence of anti-low density
lipoprotein antibodies and circulating immune complexes in aged subjects. Mechs. Ageing. Dev. 29, 117, 1985. (impakt faktor: 1,411)
58. G.A. Medgyesi, G. Fóris, G. Füst, H. Bazin: Regulation of Fcu receptor-mediated functions of
resident and provoked peritoneal macrophages. Immunobiol. 167, 293, 1984. (impakt faktor: 1,576)
59. T. Hídvégi, G.K. Fehér, T. Fehér, É. Koó, G. Füst: Inhibition of the complement activation by
an adrenal androgen dehydroepiandrosteron. Complement 1, 201-206, 1984. (impakt faktor: 1,426)
60. Hollán, S.R., Füst G., Nagy, K., Horváth, A., Králl, G., Verebélyi, K., Ujhelyi, E., Varga, L.,
Mayer, M.M.: Immunological alterations in anti-HTLV III negative haemophiliacs and homosexual men in Hungary. Immunology Letters 11, 305-310, 1985 (impakt faktor: 1,513)
61. Hídvégi, T., Füst, G., Rajnavölgyi, É., Kulics, J., Gergely, J.: Non-covalently bound C3
enhances lysis of rabbit erythrocytes through the alternative pathway. Immunology 56, 735-741, 1985. (impakt faktor: 2,952)
62. G. Füst, E. Czink, D. Minh, Zs. Miszlay, L. Varga, S.R. Hollán: Depressed classical
complement pathway activities in chronic lymphocytic leukaemia. Clin. exp. Immunol. 60, 489-495, 1985. (impakt faktor: 2,142)
63. Varga L., Dervaderics, M., Zsiray M., Kárpáthy J., Füst, G.: Granulocyte aggregating activity
in sera of workers ,ewxposed to textile dust inhalation. Diagn. Immunol. 4, 140-144, 1986. (impakt faktor: 0,844)
64. Füst, G., Miszlay, Zs., Czink, E., Varga, L., Pálóczi, K., Szegedi, Gy., Hollán S.R.: C1 and C4
abnormalities in chronic lymphocytic leukaemia and their significance. Immunol. Letts. 14, 255-259, 1986/87. (impakt faktor: 1,513)
65. Varga L., Miszlay Zs., Czink E., Pálóczi K., Szegedi Gy., Füst Gy., Hollán Zs.: Study of the
immune complex precipitation inhibiting capacity of sera of patients with chronic lymphocytic leukaemia. Diagn. Clin. Imm. 5, 129-134, 1987. (impakt faktor: 0,844)
66. Epstein J. S., Grimley P. M., Prebble O., Füst Gy., Horváth A., Hollán Zs., Pearson G. R.,
Schneider A. L., Mayner R. E., Phelan, M. A., Wells M. A., Manischewitz J. F., Armstrong G. R., Varga L., Ujhelyi E., Quinnan G. V. JR.: Absence of antibodies to human T- lymphotropic virus type III in homosexual, hemophiliac, and heterosexual men in Budapest, Hungary in 1983-84. J. Infect. Dis. 155, 134, 1987. (impakt faktor: 4,869)
67. Ujhelyi E., Füst Gy., Mihaleczky G., Králl G., Zimonyi I., Nagy K., Mayer V., Hollán Zs.:
Studies of the sensitivity and reproducibility of commercial kits to detect antibodies to the human immunodeficiency virus. Transfusion, 27, 210-212, 1987. (impakt faktor: 2,404)
68. Ujhelyi E., Onody K., Do Quang Minh, Sarkadi B., Füst Gy.: Enhancing effect of alpha
interferon on the C2 synthesis by cultured human monocytes. Immunology Letters, 15 41, 1987. (impakt faktor: 2,952)
69. Ujhelyi E., Büki B., Salavecz V., Bánhegyi D., Horváth A., Füst Gy., Hollán Zs.: A simple
method for detecting HIV antibodies hidden in circulating immune complexes. AIDS, 1, 161, 1987. (impakt faktor: 4,305)
70. Medgyesi, G.A., Kovás, J., Jenei, B., Füst, G, Merétey, K. Safety aspects of intravenous
immunoglobulins. Immunol.Invest. 17, 121-133, 1988. (impakt faktor: 1,017)
71. Varga, L., Thiry, E., Füst, G. BSA-anti-BSA immune complexes formed in the presence of
human complement do not bind to autologous red blood cells. Immunology 64, 381-384, 1988. (impakt faktor: 2,952)
72. Varga, L., Clas, F., Füst, G., Pálóczi, K., Szegedi, Gy., Loos, M., Hollán, S.R. Patients with
CLL and hypocomplementaemia have an impaired serum bactericidal activity against the Salmonella minnesota Re mutant. Complement 5, 40-45, 1988. (impakt faktor: 1,426)
73. Pálóczi, K., Ujhelyi, E., Illei, G., Füst, G., Szelényi, J., Szabó, J., Hollán, S.R.: HIV
transmission from female to male at improperly protected sexual intercourse. Lancet, i, 65, 1988. (impakt faktor: 15,871)
74. E. Ujhelyi, G. Füst, M. Katonka, M. Héjjas, S.R. Hollán: Pitfalls in HIV serology: Reagent-
dependent changes in sensitivity and specificity of ELISA kits. J.Acquired Immune Deficiency Syndromes 2, 208-211, 1989 (impakt faktor: 3,735)
75. Kramer, J., Gyódi, E., Füst, G.: Usefulness of densitometry in typing of human complement
component C4. Immunogenetics, 29, 121-123, 1989. (impakt faktor: 3,540)
76. Kramer, J., Rajczy, K., Füst, G.: Low incidence of null alleles of the fourth component of
complement (C4) in elderly people. Immunology Letts, 20, 83-85, 1989. (impakt faktor: 1,513)
77. Hidvégi T., Ermolin G.A., Efremov E.E., Dikov M.M., Kurmanova L.V., Vnashenkova G.V.,
Merkulova M.V., Kókai M., Pánya A., Füst G.: FN-C1q and C1 INH C1r-C1s complexes as indicators of complement activation in patients with CLL. Immunol.Letts. 22, 1-6, 1989. (impakt faktor: 1,513)
78. Ujhelyi, E., Füst, G., Illei, G., Allam, S., Szelényi J., Hollán, S.R.: Effect of pepsin treatment
on the HIV envelope and core antigens. AIDS 3, 383-387, 1989. (impakt faktor: 4,305)
79. Ujhelyi, E., Füst, G., Illei, G., Gyodi, E., Nagy, K., Toth, F.D., Büki, B., Dierich, M.P., Mayer,
V., Gál, Gy., Makó, J., Hollán, S.R.: Different types of false positive anti-HIV reactions in patients on haemodialysis. Immunol. Letts. 22, 35-40, 1989. (impakt faktor: 1,513)
80. Falus A., Fehér K.G., Walcz E., Brozik M., Füst G., Hidvégi T., Fehér T., Merétey K.:
Hormonal regulation of complement biosynthesis in human cell lines - I. Androgens and gamma-interferon stimulates the biosyntheis and gene expression of C1 inhibitor in human cell lines U937 and HepG2. Mol.Immunol. 27, 191-195, 1990. (impakt faktor: 1,946)
81. F.D. Tóth, J. Kiss, B. Szabó, G. Füst, E. Ujhelyi, S.R. Hollán, L. Váczi. Complement-
dependent cytotoxicity of antibodies reactive with HIV-induced cell surface antigens in HIV-carrying haemophiliacs. Acta virol. 33, 521, 1989. (impakt faktor: 0,438)
82. B. Szabó, F.D. Tóth, J. Kiss, E. Ujhelyi, G. Füst, A. Horváth, S.R. Hollán. Neutralizing
antibodies and serum interferon levels in the different stages of HIV infection. Acta. Virol. 34, 164-170, 1990 (impakt faktor: 0,438)
83. Kramer J., Kassai, T., Tauszik, T., Füst, G.: Complement C2, C3, C4, and factor B allele
distribution in the Gipsy population in Hungary. Immun. Letts. 24, 11-12, 1990. (impakt faktor: 1,513)
84. E. Ujhelyi, J. Lange, J. Goudsmit, V. Salavecz, B. Büki, G. Füst, S.R. Hollán: Correlation of
HIV core antigen, antibody and immune complex levels in sera of HIV-infected individuals. AIDS, 4, 928-929, 1990 (impakt faktor: 4,305)
85. E. Ujhelyi, D. Fuchs, G. Králl, I. Zimonyi, S. Berkessy, S. Bujdosó, K. Pálóczi, R. Mihalik, G.
Füst, H. Wachter, S.R. Hollán: Age-dependency of the progression of the-HIV-disease in haemophiliacs; Predictive value of the T cell subset and neopterin measurements Immun. Letts, 26, 67-74, 1990 (impakt faktor: 1,513)
86. T. Hidvégi, L. Varga, A. Falus, M. Kirschfink, M. Kókai, Nguyen Ahn Tuan, G. Füst:
Differences in the complement activation induced by preformed and nascent immune complexes. Complement and Inflammation, 8, 43-49, 1991 (impakt faktor: 1,426)
87. K. Pálóczi, E. Ujhelyi, D. Fuchs, R. Mihalik, D. Bánhegyi, S. Berkessy, V. Salavecz, H.
Wachter, S.R. Hollán, G. Füst: Correlation of the percentage of activated, CD3+DR+ lymphocytes to serum neopterin level in HIV seropositíve hemophiliacs. Klin. Wochschr., 69, 143-145, 1991 (impakt faktor: 0,857)
88. G. Füst, E. Ujhelyi, T. Hidvégi, K. Pálóczi, R. Mihalik, S. Hollán, K. Nagy, M. Kirschfink: The
complement system in HIV disease. Immunol. Invest., 20, 231-241, 1991. (impakt faktor: 1,017)
89. S.R. Hollán, E. Ujhelyi, K. Pálóczi, J. Szelényi, G. Illei, L. Medrano, D. Fuchs, L. István, J.
Szabó, D. Bánhegyi, F. Várnai, A. Horváth, G.A. Medgyesi, G. Füst: Results of longitudinal immunological surveillance of individuals directly or indirectly infected by a single HIV seropositive donor. Transfusion Science, 11, 73-78, 1990 (impakt faktor: 0,209)
90. Kramer J, Fülöp T, Rajczy K., Anh-Tuan N., G. Füst.A marked drop in the incidence of the
null allele of B gene of the fourth component of complement (C4B*Q0) in elderly subjects: C4B*Q0 as a probable negative selection factor for survival. Human Genetics, 86. 595- 598, 1991 (impakt faktor: 2,656)
91. Polay, A., Lakos, T., Füst, G., Kramer, J., Nguyen Ahn-Tuan, Kraszits, E., Medgyessy, I.,
Stenszky, V., Farid, N.R.: HLA-DR1 is associated with vitiligo. Immunology Letts, 27, 59- 62, 1991. (impakt faktor: 1,513)
92. L. Varga, C.A. Alper, Z. Zám, G. Füst: Decreased inhibition of immune precipitation by sera
with the C2 B allotype. Clin.Immunol. Immunopathol., 59, 65-71, 1991. (impakt faktor: 2,352)
93. D.Tóth, F., Szabó, B., Ujhelyi, E., Pálóczi, K., Horváth, A., Füst, G., Kiss, J., Bánhegyi, D.,
Hollán, S.R.: Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection. AIDS 5, 263-268, 1991. (impakt faktor: 4,305)
94. Kálmán, B., Takács, K., Gyódi, É., Kramer, J., Füst, G., Tauszik, T., Guseo, A., Kuntár, L.,
Nagy, Cs., Pálffy, Gy., Petrányi, G.Gy.: Sclerosis multiplex in Gypsies. Acta Neurol. Scand. 84, 181-185, 1991. (impakt faktor: 0,963)
95. G. Gyapay, B. Schmidt, M. Válay, A. Falus, Nguyen Anh-Tuan, A. Pánya, M. Kókai, K.
Onody, A. Mód, G. Füst: Effect of Conditioned Media of Acute Myeloid Leukaemia Blast Cells on Complement Synthesis by Cultured Human Cells of Monocyte and Hepatocyte Origin. Complement and Inflammation, 8, 370-377, 1991. (impakt faktor: 1,426)
96. Erdei, A., Füst, G., Gergely, J.: Complement and immune homeostasis. Immunology Today,
12, 332-337, 1991. (impakt faktor: 17,988)
97. Gregorek, H., KókaI, M., Hidvégi, T., Füst, G., Sabbouh, K., Madalinski, K.: Concentration of
C1 inhibitor in sera of healthy blood donors as studied by immunoenzymatic assay. Compl.Inflam, 8, 310-312, 1991. (impakt faktor: 1,426)
98. Schmidt, B., Gyapay, G., Válay, M., Füst, G.:Human Recombinant Macrophage Colony-
Stimulating Factor (M-CSF) Increases C1-Esterase Inhibitor (C1-INH) Synthesis by Human Monocytes. Immunology 74, 677-679, 1991 (impakt faktor: 2,952)
99. El Jarrah, F., Hidvégi, T., Ujhelyi, E., Gyapay, G., Salavecz, V., Origer, J-J., Hollán, S.R.,
Füst, G.: Complement activation decreases the ability of HIV transmembrane envelope protein to bind to specific antibody. AIDS, 6, 1050-1051, 1992 (impakt faktor: 4,305)
100. Falus A., Füst G., Erdei A.: Complement research: biosynthesis, genetics, immunoregulatory
role and clinical stidies. Immunology Today 13, A10-A12, 1992 (impakt faktor: 17,988)
101. Füst G.: HIV in Hungary. Immunology Today 13, A23-A24, 1992 (impakt faktor: 17,988) 102. Schmidtmayerova, H., Lackovicova, Stankova, M., Bruckova, M., Surovy, I., Ujhelyi, E.,
Füst, G., Mayer, V.: Virus neutralizing antibodies at different stages of the HIV disease: Increased levels after azidothymidine treatment. Acta Virol. 36: 157-165, 1992. (impakt faktor: 0,438)
103. Dierich, M.P., Ebenbichler, Ch., Marschang, P., Füst, G., Thielens, N., Arlaud, G.: HIV and
human complement: Mechanisms of interaction and biological implications. Immunology Today, 14, 435-440, 1993. (impakt faktor: 17,988)
104. Hidvégi, T., Prohászka, Z., Ujhelyi, E., Thielens, N.M., Dierich, M.P., Hampl, H., Arlaud, G.,.
Nagy, K., Füst, G.: Studies on the mechanism of complement-mediated inhibition of antibody binding to HIV gp41. Clin.exp.Immunol.,94, 490-493, 1993. (impakt faktor: 2,142)
105. Füst, G., Tóth, F.D., Kiss, J., Ujhelyi, E., Nagy, I., Bánhegyi, D.: Neutralizing and enhancing
antibodies measured in complement-restored serum samples from HIV-1-infected individuals correlate with immunosuppression and disease. AIDS, 8, 603-609, 1994. (impakt faktor: 4,305)
106. Kramer, J., Rajczy, K., Hegyi, L., Fülöp, T., Mohácsi, A., Mezei, Zs., Keltai, L., Blaskó, G.,
Ferenczy, E., Nguyen Anh-Tuan, Füst G.: C4B*Q0 allotype as risk factor for myocardial infarction. Br.Med.J. 309, 313-314, 1994. (impakt faktor: 4,338)
107. D. Tóth, F., Süsal C., Ujhelyi, E., Bánhegyi, D., Kiss, J., Daniel, V., Nagy, I., Opelz, G., Füst,
G.: Comparative study of antibodies that are associated with disease progression in HIV disease. Imm.Letts. 41, 33-36, 1994. (impakt faktor: 1,513)
108. Varga, L., Czink, E., Miszlay, Zs., Pálóczi, K., Bányai, A., Füst, G.: Low activity of the
classical complement pathway predicts short survival of patients with chronic lymphocytic leukaemia. Clin.exp.Immunol., 99, 112, 1995 (impakt faktor:2,680)
109. Varga, L., Poros, A., Puskás, É., Pánya, A., Kramer, J., Gyódi, É., Füst, G.: Clinical
significance of longitudinal complement measurements in bone marrow transplant patients. Bone Marrow Transplantation., 15, 509-514, 1995 (impakt faktor: 2,234)
110. Stachowski, J., Kramer, J., Füst, G., Maciejewski, J., Baldamus, C., Petrányi, G.Gy.:
Relationship between the reactivity to hepatitis B virus vaccination and the frequency of MHC class I, II and III alleles in haemodialysis patients. Scand.J.Immunol. 42, 60-65, 1995 (impakt faktor: 1,894)
111. Prohászka, Z., Hidvégi, T., Ujhelyi, E., Stoiber, H., Dierich, M.P., Süsal, C., Füst, G.:
Interaction of complement and specific antibodies with the external glycoprotein 120 of HIV-1. Immunology 85, 184-189, 1995 (impakt faktor: 2,867)
112. Füst, G., Dierich, M.P., Hidvégi, T.: Role of humoral factors in the progression of HIV
disease. Immunology Today, 16, 167, 1995 (impakt faktor: 19.590)
113. Hidvégi, T., Schmidt, B., Varga, L., Dervaderics, M., Lantos, Á., Gönczi, Sz., Barok, J.,
Kirschfink, M., Spath, P., Füst, G.: In vitro complement activation by ragweed allergen extract in the sera of ragweed allergic and non-allergic persons. Immunol. Letts. 48, 65- 71, 1995. (impakt faktor: 1,241)
114. Németh, A., Szakmary, K., Kramer, J., Dinya, E., Pados, Gy., Fust, G., Huettinger, M.:
Apolipoprotein E and complement C3 polymorphism and their role in the response to Gemfibrozil and low fat cholesterol therapy. Eur.J.Clin.Chem.Biochem. 33, 799-804, 1995. (impakt faktor: 0,956)
115. Hidvégi, T., Berrens, L., Varga, L., Maranon, F., Schmidt, B., Kirschfink, M., Füst G.:
Comparative study of the complement-activating and specific IgE-binding properties of ragweed pollen allergen. Clin.exp.Immunol. 108, 122-127, 1997. (impakt faktor: 2,546)
116. Prohászka, Z., Nemes, J., Hidvégi, T., Tóth, F.D., Kerekes, K., Erdei, A., Szabó, J.,
Thielens, N., Dierich, M.P., Spath, P., Ghebrehiwet, B., Hampl, H., Arlaud, G., Füst, G.: Two parallel routes of the complement-mediated antibody-dependent enhancement of the human immunodeficiency virus type 1 infection, AIDS, 11, 949-958, 1997. (impakt faktor: 5,227)
117. Gönczi, Zs., Varga, L., Hidvégi, T., Schmidt, B., Pánya, A., Kókai, M., Füst, G.: The severity
of clinical symptoms in ragweed-allergic patients is related to the extent of ragweed- induced complement activation in their sera. Allergy, 52, 1110-1114, 1997 (impakt faktor: 1,096)
118. Kramer J., Stachowski J, Barth C., Ujhelyi E., Tarján V., Sulowicz W., Füst G., Baldamus
C.A.: Genetic regulation of the impaired immune response to hepatitis B vaccine associated with low TCR density in end stage renal disease patients: contribution of complement C4 and factor B alleles. Immun.Letts, 59, 13-19, 1997 (impakt faktor: 1,241)
119. Prohászka Z., Német K., Csermely P., Hudecz F., Mezô G., Füst. G.: Defensins purified
from human granulocytes bind C1q and activate the classical complement pathway like the transmembrane glucoprotein gp41 of HIV-1. Mol.Immunol., 34, 809-816, 1997 (impakt faktor:2,330)
120. Füst G.: Enhancing antibodies in HIV infection. A review. in “Survival of parasites, microbes
and tumours: strategies for evasion, manipulation and exploitation of the immune response. Supplement to Parasitology Volume 115 (1997) Edited by MJ Doenhoff and LH Chappell, 115, S127-S140 (impakt faktor:1,808)
121. Prohászka Z., Thiel S., Ujhelyi E., Szlávik J., Bánhegyi D., Füst G.: Mannan-binding lectin
(MBL) serum concentrations are dependent on the stage of disease in HIV infected patients. Immun.Letts, 58, 171-175, 1997, (impakt faktor: 1,241)
122. Tarján V., Ujhelyi E., Kellner R., Králl G., Gyuris Á., Mihály I., Füst G.: Three cases of
transient HIV-seropositivity observed in ten year practice of a national AIDS confirmatory laboratory. AIDS, 12, 120-121, 1998, (impakt faktor: 5,227)
123. Prohászka Z., Bánhegyi D., Ujhelyi E., Karádi I., Füst G.: Antibodies against 60 kD heat
shock proteins in human immunodeficiency vírus infection. In Stress of Life from Molecules to Man (ed.:P.Csermely) Ann.N.Y Acad. Sci, 851:94-98, 1998 (impakt faktor: 0.903)
124. Dervaderics, M., Hidvégi, T., Schmidt, B., Füst, G., Varga, L.: Ragweed allergy: correlation
between skin reactivity and in vitro complement activation. Immunol.Letts. 64, 119-123, 1998. (impakt faktor: 1.096)
125. L. Bíró, Gy. Domján, A. Falus, L. Jakab, K. Cseh, L. Kalabay, G. Tarkovács, J. Kramer, Z.
Prohászka, J. Jákó, G. Füst, A. Császár. Relationship among the levels of complement components, acute phase proteins and some cytokines in patients with multiple myeloma. European Journal of Clinical Investigation 28:679-686, 1998. (impakt faktor: 1.693)
126. Z. Prohászka, G. Füst: Contribution of complement to defensin action in eye. The Lancet
352, 1152, 1998 (letter).(impakt faktor: 8.060)
127. Farkas H., Gyeney L., Nemesánszky E., Káldi G., Kukán F., Masszi I., Soós J., Bély M.,
Farkas E., Füst G., Varga L.: Coincidence of hereditary angioedema (HAE) with Crohn’s disease. Immunol. Invest. 28, 43-53, 1999 (impakt faktor: 0.787)
128. Prohászka Z., Daha MR, Süsal C, Daniel V, Szlávik J., Bánhegyi D, Nagy K, Várkonyi V,
Horváth A, Ujhelyi E, Tóth FD, Uray K, Hudecz F, Füst G.: C1q autoantibodies in HIV infection: Correlation to elevated levels of autoantibodies against 60-kDa heat-shock proteins. Clin.Immunol. 90, 247-255, 1999 (impakt faktor: 1,891)
129. Z. Prohászka, J. Duba, G. Lakos, E. Kiss, L. Varga, L. Jánoskuti, A. Császár, I. Karadi, K.
Nagy, M. Singh, L. Romics, and G. Füst: Antibodies against human hsp60 and mycobacterial hsp65 differ in their antigen specificity and complement activating ability. International Immunology 11, 1363-1370, 1999 (impakt faktor: 3.548)
130. Farkas, H., Gyeney L., Gidófalvy, F, Füst G., Varga, L.: The efficacy of short-term dnazol
prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures. J.Oral Maxillofac.Surg. 57, 404-408, 1999 (impakt faktor: 0.641)
131. Farkas, H., Csepregi, A., Nemesánszky, E., Pár, A., Gyeney, L., Varga, L., Füst, G.:
Acquired angioedema associated with chronic hepatitis C. J.Allergy Clin.Immunol. 103, 711-712, 1999 (impakt faktor: 3,769)
132. . Farkas H., Gyeney, L., Majthényi, P., Füst, G., Varga, L.: Angioedemea due to acquired
C1-esterase inhibitor deficiency in a patient with Helicobacter pylori infection. Z.Gasroenterol. 37, 513-518, 1999 (impakt faktor: 1,021)
133. Szabó J., Prohászka Z., Tóth F.D., Gyuris, Á., Segesdi, J., Bánhegyi, D., Ujhelyi E.,
Minárovits, J. Füst G. Strong correlation between the complement-mediated antibody- dependent enehancement of HIV-1 infection and plasma viral load. AIDS 13, 1841-1849, 1999 (impakt faktor: 5,050)
134.Speth, C., Prohászka, Z., Mair, M., Stöckl, G., Zhu, X., Jöbst, B., Füst, G., Dierich M.P. A 60
kD heat-shock protein-like molecule interacts with the HIV transmembrane glycoprotein gp41: Molecular Immunology 36, 619-628, 1999 (impakt faktor: 1,800)
135 Farkas H., Harmat G, Gyeney L., Füst G, Varga L. Danazol therapy for hereditary angiedema
in children Lancet, 354, 1030-1032, 1999. (impakt faktor: 0)
136. Nagy G, Brózik M, Varga L, Füst G, Kirschfink M, Kiss E, Gergely P.: Usefulness of
detection of complement activation products in evaluating SLE activity. Lupus 9, 19-25, 2000. (impakt faktor: 2,514)
137. Bíró L, Varga L, Pár A, Nemesánszky E, Csepregi A, Telegdy L, Ibráni E, Dávid K, Horváth
G, Szentgyörgyi L, Nagy I, Dalmi L, Abonyi M, Füst G, Horányi M: Changes in the acute phase complement component and IL-6 levels in patients with chronic hepatitis C receiving interferon α-2b. Immunology Letters 72, 69-74, 2000 (impakt faktor: 1,546)
138. Kramer J, Harcos P, Prohászka Z, Horváth L, Karádi I, Singh M, Császár A, Romics L, Füst
G: Frequencies of certain complement protein alleles and serum levels of anti-heat-shock protein antibodies in cerebrovascular diseases. Stroke 31, 2648-2652, 2000.( impakt faktor: 6,008)
139. Bíró L, Varga L, Pár A, Nemesánszky E, Telegdy L, Ibrányi E, Dávid K, Horváth G,
Szentgyörgyi L, Nagy I, Dalmi L, Abonyi M, Füst G, Horányi M, Csepregi A: C5b-9 and interleukin-6 in chronic hepatitis C. Surrogate markers predicting short-term response to interferon alpha-2b. Sc. J. Gatroenterol. 35, 1092-1096, 2000. (impakt faktor: 1,842)
140. Horváth L, Czirják L, Fekete B, Jakab L, Prohászka Z, Cervenák L, Romics L, Singh M,
Daha M.R., Füst G.: Levels of antibodies against C1q and 60 kDa family of heat shock proteins in the sera of patients with various autoimmune diseases, Immmunology Letters 75, 103-109, 2001. (impakt faktor: 1,546)
141. Z Prohászka, J Duba, L Horváth, A Császár, I Karádi, A Szebeni, M Singh, B Fekete, L
Romics, G Füst: Comparative study on antibodies to human and bacterial 60 kD heat shock proteins in a large cohort of patients with coronary heart disease and healthy subjects. Eur.J.Clin.Invest. 31, 285-292, 2001 ((impakt faktor: 2,071).
142. K Burian, Z Kis, D Virok, V Endresz, Z Prohaszka, J Duba, K Berencsi, K Boda, L Romics,
G Fust, E Gonczol: Independent and Joint Effects of Antibodies to Human Heat-Shock Protein 60 and Chlamydia pneumoniae Infection in the Development of Coronary Atherosclerosis. Circulation 103, 1503-1508, 2001 (impakt faktor: 10,893)
143. A Horváth, G. Füst, I. Horváth, G. Vallus, J. Duba, P. Harcos, Z. Prohászka, É. Rajnavölgyi,
L. Jánsokuti, M.Kovács, A. Császár, L. Romics, I. Karádi.: Anti-cholesterol antibodies in patients with different atherosclerotic vascular diseases and healthy individuals. Characterization of human ACHA. Atherosclerosis 156, 185-192, 2001 (impakt faktor: 3,386).
144. J Szabó, L Cervenák, F D Tóth, Z Prohászka, L Horváth, K Kerekes, Z Beck, A Bácsi, A
Erdei, EIB Reerschke, G Füst, B Ghebrehiwet: Soluble gC1q-R/p33, a cell protein that binds to the globular „heads” of C1q, effectively inhibits the growth of HIV-1 strains in cell cultures. Clin. Immunol. 99, 222-231, 2001.( impakt faktor: 2,377)
145. Á Kalina, A. Császár, G. Füst, B. Nagy, Cs. Szalai, I. Karádi, J. Duba, Z. Prohászka, L.
Horváth, H. Dieplinger. The association of serum lipoprotein levels, apolipoprotien size and (TTTA)n polymorphism with coronary heart disease. Clinica Chimica Acta 309, 45-51,
2001 (impakt faktor: 1,041)
146. G Nagy, A Horváth, G Füst, L. Romics, P.Gergely, I Karádi: Anticholesterol antibody levels
in patients with sytemic lupus erythematosus Ann Rheum Dis 60, 722-723, 2001 (impakt faktor: 2,444)
147. A Horváth, D Bánhegyi, A. Bíró, E. Ujhelyi, A. Veres, L.Horváth, Z. Prohászka, A. Bácsi, V.
Tarján, L. Romics, I. Horváth, F. D. Tóth, G. Füst, I. Karádi: High Level of anticholesterol antibodies (ACHA) in HIV patients. Normalization of serum ACHA concentration after introduction of HAART. Immunobiology 203, 756, 2001 (impakt faktor: 2,416).
148. L. Horváth, L. Czirják, B.Fekete, L.Jakab, T. Pozsonyi, L. Kalabay, L. Romics, K. Miklós, L.
Varga, Z. Prohászka, A. Szakács, E. Nagy, M.R. Daha, G.Füst: High levels of antibodies against C1q are associated with the disease activity and nephritis but not with other organ manifestations in SLE patients. Clin. Exp.Rheumatol., 19, 667-672, 2001.( impakt faktor: 1,638)
149 Császár A., Duba J., Melegh B., Kramer J., Szalai Cs., Prohászka Z., Karádi I., Kovács M.,
Méhes K., Romics L., Füst G.: Increased frequency of the C3*F allele and the Leiden mutation of coagulation factor V in patients with severe coronary heart disease who survived myocardial infarction. Exp. Clin. Immunogenetics 18, 206-212, 2001 (impakt faktor: 2,400)
150. H. Farkas, G. Füst, B. Fekete, I. Karádi, L. Varga: Eradication of Helicobacter pylori and
improvement of hereditary angioneurotic oedema. Research Letter. Lancet 358, 1695- 1696, 2001 (impakt faktor: 10,232)
151. Cs. Szalai, G. Füst, J Duba, J Kramer, L Romics, Z Prohászka, A. Császár: Association of
polymorphisms and allelic combinations in the tumour necrosis.α-complement MHC
region with coronary artery disease. J. Med. Genet. 39: 46-51 2002. (impakt faktor: 3,290)
152. Z. Prohászka, M. Singh, K. Nagy, E. Kiss, G. Lakos, J. Duba, G. Füst: Heat shock protein 70
is a potent activator of the human complement system Cell Stress and Chaperones 7, 17- 22, 2002 (impakt faktor: 3,436)
153. Veres A., Prohászka Z., Kilpinen S., Singh M., Füst G., Hurme M.: The promoter
polymorhism of the IL-6 gene is associated with levels of antibodies to 60-kDa heat-shock proteins. Immunogenetics 53, 851-856, 2002 (impakt faktor: 2,142)
154. Kalabay L., Jakab L., Prohászka Z., Füst G., Benkö Zs., Telegdy L., Lörincz Zs., Závodszky
P., Arnaud P, Fekete B.: Human fetuin/α2HS-glycoprotein level as a novel indicator of liver cell function and short-term mortality in patients with liver cirrhosis and liver cancer. Eur. J. Gastrenterol. Hepatol. 14, 1-6, 2002. (impakt faktor: 1,142)
155. Bene L., Füst G., Huszti Z., Hernádi Zs., Fekete B., Mészáros M., Veres A., Kovács Á.,
Miklós K., Sing M., Romics L., Prohászka Z.: Impaired humoral immune rsponse against mycobacterial 65-kDa heat shock protein (HSP65) in patients with inflammatory bowel disease. Di. Dis. Sci, 2002, (impakt faktor: 1,516)
156. L. Horváth, L. Cervenak, M. Oroszlán, Z. Prohászka, K. Uray, F. Hudecz, É. Baranyi, L.
Madácsy, M. Singh, L. Romics G. Füst a,b and P. Pánczél. Antibodies against different epitopes of heat-shock protein 60 in children with type 1 diabetes mellitus, Immunology Letters, 80, 151-154, 2002 (impakt faktor: 1,546)
157. Veres A., Szamosi T, Ablonczy M, Szamosi T.Jr., Singh M, Karádi I, Romics L, Füst G,
Prohászka Z.: Complement activating antibodies against the human 60 kDa heat shock protein as a new independent family risk factor of coronary heart disease. Eur. J. Clin. Invest. 32, 405-410, 2002. (impakt faktor: 2,255)
158. L Kalabay, B Fekete, L Czirják, L Horváth, M R. Daha, A Veres, G Fónyad, A Horváth, Á
Viczián, M Singh, I Hoffer, G Füst, L Romics Z. Prohászka: Helicobacter pylori Infection in Connective Tissue Disorders is Associated with High Levels of Antibodies to Mycobacterial hsp65 but not to Human hsp60. Helicobacter 7, 250-256, 2002. (impakt faktor: 2,737)
159. M Dervaderics, G Füst, M Ótos, J. Barok, G Pataky: Differences in the Sensitisation to
ragweed pollen and occurrence of late Summer allergic symptoms between native and immigrant workers of the nuclear power plant of Hungary. Immunol. Invest. 31, 29-40, 2002. (impakt faktor: 1,190)
160. L Kalabay, L Jakab, Z Prohászka, G Füst, Zs Benkö, L Telegdy, P Závodszky, P Arnaud, B
Fekete: Human fetuin/α2HS-glycoprotein level as a novel indicator of liver cell function and short-term mortality in patients with liver cirrhosis and liver cancer. Eur. J. Gastroenterol and Hepatol 14, 1-6, 2002. (impakt faktor: 1,580)
161. L Horváth, A Császár, A Falus, H Dieplinger, A Horváth, É Puskás, G Halm, A Bányai, K
Pálóczi, E László, L Kalabay, L Romics, G Füst: IL-6 and lipoprotein (a) [Lp(a)] concentrations are related only in patients with high apo(a) isoforms in monoclonal gammopathy. Cytokine, 18, 340-343, 2002 (impakt faktor: 1,992)
162. Kerényi Á, Gy Nagy, A Veres, L Varga, Á Füst, A Nagymihály, N Czumbel, I Süveges, G.
Füst: C1r-C1s-C1-inhibitor (C1rs-C1inh) complex measurements in tears of patients before and after penetrating keratoplasty. Current Eye Research 24, 99-104, 2002. (impakt faktor: 1,300)
163. S Rugonfalvi-Kiss, V Endrész, H O. Madsen, K Burián, J Duba, Z Prohászka, I Karádi, L
Romics, É Gönczöl, G Füst, P Garred: Association of Chlamydia pneumoniae With Coronary Artery Disease and Its Progression Is Dependent on the Modifying Effect of Mannose-Binding Lectin. Circulation 106, 1071-1076, 2002 (impakt faktor: 10,517)
164. Vatay Á, Rajczy K, Pozsonyi É, Hosszúfalusi N, Prohászka Z, Füst G, Karádi I, Szalai Cs,
Grósz A, Bártfai Z, Pánczél P: Differences in the genetivc background of latent autoimmune diabetes in adults (LADA) and type 1 diabetes mellitus. Immunol. Letters 84, 109-115, 2002. (impakt faktor: 2,009)
165 J Kocsis, A Veres, Á Vatay, J Duba, I Karádi, G Füst, Z Prohászka: Antibodies against the
human heat shock protein hsp70 in patients with severe coronary artery disease. Immunol. Invest 31, 219-231, 2002 (impakt faktor: 1,190)
166. A Veres, G Füst, M Smieja, M McQueen, A Horváth, Qilong Yi, A Bíró, J Pogue, L Romics, I
Karádi, M Singh, J Gnarpe, Z Prohászka, S Yusuf for the Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Relationship of Anti-60 kDa Heat Shock Protein and Anti-Cholesterol Antibodies to Cardiovascular Events, Circulation 106, 2775-2780, 2002. (impakt faktor: 10,517)
167. Hosszúfalusi N, Vatay Á, Rajczy K, Prohászka Z, Pozsonyi É, Horváth L, Grósz A, Gerő L,
Madácsy L, Romics L, Karádi I, Füst G., Pánczél P.: Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 26, 452-457, 2003 (impakt faktor: 5,477)
168. L. Varga, K. Szilágyi, Zs. Lőrincz, L. Berrens, S. Thiel, P. Závodszky, M.R. Daha, N.M.
Thielens, G.J. Arlaud, K. Nagy, P. Spath, G. Füst. Studies on the mechanisms of allergen- induced activation of the classical and lectin pathways of complement Mol. Immunol. 39, 839-846, 2003 (impakt faktor: 2,414)
169. Yu, C.Y., Chung, E.K., Yang, Y., Blanchong, C.A., Jacobsen, N., Saxena,K., Yang, Z.,
Miller, W., Varga, L., and Fust,G. Dancing with complement C4 and the RP-C4-CYP21- TNX (RCCX) modules of the major histocompatibility complex. Progr. Nucl. Acid Res. Mol. Biol. 75: 217-292, 2003. (impakt faktor: 4,839)
170. Farkas H, Harmat G, Füst G, Varga L, Visy B.: Clinical management of hereditary angio-
edema in children Pediatric Allergy and Immunology 13, 153-151, 2002 (impakt faktor: 1,807)
171. Vatay A, Bene L, Kovacs A, Prohaszka Z, Szalai C, Romics L, Fekete B, Karadi I, Fust:
Relationship between the tumor necrosis factor alpha polymorphism and the serum C- reactive protein levels in inflammatory bowel disease. Immunogenetics. 2003 55:247-52. (impakt faktor: 2.475)
172 Vatay A, Yang Y, Chung EK, Zhou B, Blanchong CA, Kovacs M, Karadi I, Fust G, Romics L
L, Varga L, Yu CY, Szalai C. : Relationship between complement components C4A and C4B diversities and two TNFA promoter polymorphisms in two healthy Caucasian populations. Hum Immunol. 2003 64:543-52. (impakt faktor: 2,573)
173. Biro A, Horvath A, Varga L, Nemesanszky E, Csepregi A, David K, Tolvaj G, Ibranyi E,
Telegdy L, Par A, Romics L, Karadi I, Horanyi M, Gervain J, Ribiczey P, Csondes M, Fust G.: Serum anti-cholesterol antibodies in chronic hepatitis-C patients during IFN-alpha-2b treatment. Immunobiology, 207, 161-168, 2003. (impakt faktor: 1.319)
174. László Bene, George Füst, Béla Fekete, Ágota Kovács, Laura Horváth Zoltán Prohászka,
Kata Miklós, Gábor Pálos, Mohamed Daha, Henriette Farkas and Lilian Varga: High Normal Serum Levels of C3 and C1-inhibitor, Two Acute Phase Proteins Belonging to the Complement System, Occur More Frequently in Patients with Crohn’s Disease than in Ulcerative Colitis. Dig. Dis. Sci. 2003 Jun;48(6):1186-92. (impakt faktor: 1.498)
175. Bakos N, Fekete B, Prohászka Z, Füst G, Kalabay L. High prevalence of IgG and IgA
antibodies to 19-kDa Helicobacter pylori-associated lipoprotein in chronic urticaria. Allergy. 2003 Jul;58(7):663-7 (impakt faktor: 3.666)
176. Bánhegyi D, Bácsi A, Tóth FD, Prohászka Z, Horváth A, Beck Z, Kónya J, Füst G.
Significant decrease of the enhancement/neutralization index in HIV patients during highly active antiretroviral therapy (HAART). Immunol Lett. 2003 Oct 9;89(1):25-30. (impakt faktor: 1.847)
177. Kocsis Judit, Prohászka Zoltán, Bíró Adrienn, Füst George, and Bánhegyi Dénes. Elevated
levels of antibodies against 70 kD heat shock proteins (Hsp70) in sera of patients with HIV infection. J Med Virol. 2003 Dec;71(4):480-2., (impakt faktor: 2.629)
178. Yang Y, Chung EK, Zhou B, Blanchong CA, Yu CY, Fust G, Kovacs M, Vatay A, Szalai C,
Karadi I, Varga L.: Diversity in intrinsic strengths of the human complement system: serum c4 protein concentrations correlate with c4 gene size and polygenic variations, hemolytic activities, and body mass index. J Immunol. 2003 Sep 1;171(5):2734-45 (impakt faktor: 7,014)
179. Uray K, Hudecz F, Füst G, Prohászka Z. Comparative analysis of linear antibody epitopes
on human and mycobacterial 60-kDa heat shock proteins using samples of healthy blood donors. Int Immunol. 2003 Oct;15(10):1229-1236. (impakt faktor: 3.595)
180. Pandey JP, Prohaszka Z, Veres A, Fust G, Hurme M. Epistatic effects of genes encoding
immunoglobulin GM allotypes and interleukin-6 on the production of autoantibodies to 60- and 65-kDa heat-shock proteins. Genes Immun 5, 64-71, 2004 (impact factor: 3,060)
181. Szalai C, Keszei M, Duba J, Prohaszka Z, Kozma GT, Csaszar A, Balogh S, Almassy Z,
Fust G, Czinner A. Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease. Atherosclerosis. 2004 Mar;173(1):109-14. (impact factor: 3,603)
182. Prohaszka Z, Fust G. Immunological aspects of heat-shock proteins-the optimum stress of
life. Mol Immunol. 2004 May;41(1):29-44 (impact factor: 2,827)
183. Quintana FJ, Buzas E, Prohaszka Z, Biro A, Kocsis J, Fust G, Falus A, Cohen IR. Knock-out
of the histidine decarboxylase gene modifies the repertoire of natural autoantibodies. J Autoimmun. 2004 Jun;22(4):297-305. (impact factor: 2,353)
184 Visy B, Fust G, Varga L, Szendei G, Takacs E, Karadi I, Fekete B, Harmat G, Farkas H. Sex
hormones in hereditary angioneurotic oedema. Clin Endocrinol (Oxf). 2004 Apr;60(4):508- 15. (impact factor: 2,767)
185. Arason GJ, Bodvarsson S, Sigurdarson ST, Sigurdsson G, Thorgeirsson G, Gudmundsson
S, Kramer J, Fust G. An age-associated decrease in the frequency of C4B*Q0 indicates that null alleles of complement may affect health or survival. Ann N Y Acad Sci. 2003 Dec;1010:496-9. (impact factor: 1,892)
186. Kalabay L, Nemesanszky E, Csepregi A, Pusztay M, David K, Horvath G, Ibranyi E, Telegdy
L, Par A, Biro A, Fekete B, Gervain J, Horanyi M, Ribiczey P, Csondes M, Kleiber M, Walentin S, Prohaszka Z, Fust G. Paradoxical alteration of acute-phase protein levels in patients with chronic hepatitis C treated with IFN-alpha2b. Int Immunol. 2004 Jan;16(1):51-4. (impact factor: 3,690)
187. Kalmar L, Bors A, Farkas H, Vas S, Fandl B, Varga L, Fust G, Tordai A. Mutation screening
of the C1 inhibitor gene among Hungarian patients with hereditary angioedema. Hum Mutat. 2003 Dec;22(6):498. (impact factor: 6,845)
188. Fust G, Arason GJ, Kramer J, Szalai C, Duba J, Yang Y, Chung EK, Zhou B, Blanchong CA,
Lokki ML, Bodvarsson S, Prohaszka Z, Karadi I, Vatay A, Kovacs M, Romics L, Thorgeirsson G, Yu CY: Genetic basis of tobacco smoking: strong association of a specific major histocompatibility complex haplotype on chromosome 6 with smoking behavior. Intern.Immunol. 16,1507,2004. (impact factor: 3,543)
189. Agostoni A, Aygoren-Pursun E, Binkley KE, Blanch A, Bork K, Bouillet L, Bucher C,
Castaldo AJ, Cicardi M, Davis AE, De Carolis C, Drouet C, Duponchel C, Farkas H, Fay K, Fekete B, Fischer B, Fontana L, Fust G, Giacomelli R, Groner A, Hack CE, Harmat G, Jakenfelds J, Juers M, Kalmar L, Kaposi PN, Karadi I, Kitzinger A, Kollar T, Kreuz W, Lakatos P, Longhurst HJ, Lopez-Trascasa M, Martinez-Saguer I, Monnier N, Nagy I, Nemeth E, Nielsen EW, Nuijens JH, O'grady C, Pappalardo E, Penna V, Perricone C, Perricone R, Rauch U, Roche O, Rusicke E, Spath PJ, Szendei G, Takacs E, Tordai A, Truedsson L, Varga L, Visy B, Williams K, Zanichelli A, Zingale L. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004 Sep;114(3 Suppl):S51- 131. (impact factor: 7,205)
190. Fust G, Beck Z, Banhegyi D, Kocsis J, Biro A, Prohaszka Z. Antibodies against heat shock
proteins and cholesterol in HIV infection. Mol Immunol. 2005 Jan;42(1):79-85. (impact factor: 3,196)
191. Szeplaki G, Prohaszka Z, Duba J, Rugonfalvi-Kiss S, Karadi I, Kokai M, Kramer J, Fust G,
Kleiber M, Romics L, Varga L. Association of high serum concentration of the third component of complement (C3) with pre-existing severe coronary artery disease and new vascular events in women. Atherosclerosis. 2004 Dec;177(2):383-9. (impact factor: 3,796)
192. Huszti Z, Bene L, Kovacs A, Fekete B, Fust G, Romics L, Singh M, Prohaszka Z. Low levels
of antibodies against E. coli and mycobacterial 65kDa heat shock proteins in patients with inflammatory bowel disease. Inflamm Res. 2004 Oct;53(10):551-5. (impact factor: 1,450)
193. Janoskuti L, Forhecz Z, Hosszufalusi N, Kleiber M, Walentin S, Balint O, Duba J,
Rugonfalvi-Kiss S, Romics L, Karadi I, Fust G, Prohaszka Z. High levels of C-reactive protein with low total cholesterol concentrations additively predict all-cause mortality in patients with coronary artery disease. Eur J Clin Invest. 2005 Feb;35(2):104-11 (impact factor: 2,346)
194. Dosa E, Rugonfalvi-Kiss S, Prohaszka Z, Szabo A, Karadi I, Selmeci L, Romics L, Fust G,
Acsady G, Entz L. Marked decrease in the levels of two inflammatory markers, hs-C- reactive protein and fibrinogen in patients with severe carotid atherosclerosis after eversion carotid endarterectomy. Inflammation Res. 2004 Nov;53(11):631-5. (impact factor: 1,450)
196. Szeplaki G, Varga L, Valentin S, Kleiber M, Karadi I, Romics L, Fust G,Farkas H. Adverse
effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema.J Allergy Clin Immunol. 2005 Apr;115(4):864-9. (impact factor: 7,205)
197. Rugonfalvi-Kiss S, Dosa E, Madsen HO, Endresz V, Prohaszka Z, Laki J, Karadi I, Gonczol
E, Selmeci L, Romics L, Fust G, Entz L, Garred P. High rate of early restenosis after carotid eversion endarterectomy in homozygous carriers of the normal mannose-binding lectin genotype.Stroke. 2005 May;36(5):944-8. Epub 2005 Mar 24. (impact factor: 5,748)
198. Dosa E, Rugonfalvi-Kiss S, Prohaszka Z, Szabo A, Karadi I, Selmeci L, Romics L, Fust G,
Acsady G, Entz L. Marked decrease in the levels of two inflammatory markers, hs-C- reactive protein and fibrinogen in patients with severe carotid atherosclerosis after eversion carotid endarterectomy.Inflamm Res. 2004 Nov;53(11):631-5. (impact factor: 1,450)
199. Fust G, Beck Z, Banhegyi D, Kocsis J, Biro A, Prohaszka Z. Antibodies against heat shock
proteins and cholesterol in HIV infection.Mol Immunol. 2005 Jan;42(1):79-85. Review. (impact factor: 3,196)
200 Dosa E, Szabo A, Prohaszka Z, Karadi I, Rugonfalvi-Kiss S, Apor A, Jaranyi Z,Huttl K,
Selmeci L, Acsady G, Fust G, Entz L.Changes in the plasma concentration of soluble thrombomodulin in patients with severe carotid artery stenosis after eversion endarterectomy. Inflamm Res. 2005 Jul;54(7):289-94. (impact factor: 1,450)
201. Papp D, Prohaszka Z, Kocsis J, Fust G, Banhegyi D, Raynes DA, Guerriero V.Development
of a sensitive assay for the measurement of antibodies against heat shock protein binding protein 1 (HspBP1): increased levels of anti-HspBP1 IgG are prevalent in HIV infected subjects. J Med Virol. 2005 Aug;76(4):464-9. (impact factor 2,331)
202 . Biro A, Dosa E, Horvath A, Prohaszka Z, Rugonfalvi-Kiss S, Szabo A, Karadi I, Acsady G,
Selmeczi L, Entz L, Fust G, Romics L.Dramatic changes in the serum levels of anti- cholesterol antibodies after eversion endarterectomy in patients with severe carotid atherosclerosis. Immunol Lett. 2005 Jun 15;99(1):51-6. Epub 2005 Jan 19. (impact factor 2,136)
203. Hermann C, Krikovszky D, Fust G, Kovacs M, Korner A, Szabo A, Vannay A, Madacsy L.
Association between interleukin-6 polymorphism and age-at-onset of type 1. diabetes. Epistatic influences of the tumor necrosis factor-alpha and interleukin-1beta polymorphisms. Eur Cytokine Netw. 2005 Dec;16(4):277-81 (impact factor: 1,747)
204. Szebeni A, Schloot N, Kecskemeti V, Hosszufalusi N, Panczel P, Prohaszka Z, Fust, G,
Uray K, Hudecz F, Meierhoff G. Th1 and Th2 cell responses of type 1 diabetes patients
and healthy controls to human heat-shock protein 60 peptides AA437-460 and AA394- 408. Inflamm Res. 2005 Oct;54(10):415-9. (impact factor: 1,450)
205. Harcos P, Laki J, Kiszel P, Szeplaki Z, Szolnoki Z, Kovacs M, Melegh B, Szeplaki G, Fust
G, Blasko B.Decreased frequency of the TNF2 allele of TNF-alpha -308 promoter polymorphism is associated with lacunar infarction. Cytokine. 2006, 33, 100-105, (impact factor: 1,986)
206. Szilagyi A, Blasko B, Szilassy D, Fust G, Sasvari-Szekely M, Ronai Z. Real-time PCR
quantification of human complement C4A and C4B genes.BMC Genet. 2006 Jan 10;7:1 (impact factor: 0,924)
207. Biro A, Thielens NM, Cervenak L, Prohaszka Z, Fust G, Arlaud GJ.Modified low density
lipoproteins differentially bind and activate the C1complex of complement.Mol Immunol. 44, 1169-77, 2007. (impact factor: 3,742)
208. Oroszlan M, Daha MR, Cervenak L, Prohaszka Z, Fust G, Roos A: MBL and C1q compete
for interaction with human endothelial cells. Mol. Immunol. 44, 1150-58, 2007 (impact factor: 3,742)
209. Molvarecz A, Prohaszka Z, Nagy B, Szalay J, Fust G, Karadi I, Rigó J Jr: Association of
elevated serum heat-shock protein 70 concentration with transient hypertension of pregnancy, preeclampsia and superimposed preeclampsia: a case-control study.J Hum Hypertens. 20, 780-786, 2006 (impact factor: 2,960)
210. Lilian Varga Gábor Széplaki, Beáta Visy, George Füst, George Harmat, Katalin Miklós,
Julianna Németh, László Cervenak, István Karádi, Henriette Farkas: C1-inhibitor (C1-INH) autoantibodies in hereditary angioedema. Strong correlation with the severity of disease in C1-INH concentrate naïve patients. Mol. Immunol. 44, 1654-60, 2007 (impact factor: 3,742)
211. Szilagyi, A.Blasko, B.Ronai, Z.Fust, G.Sasvari-Szekely, M.Guttman, A.: Rapid quantification
of human complement component C4A and C4B genes by capillary gel electrophoresis. Electrophoresis, 27, 1437-1443, 2006 (impact factor: 4,101)
212. Laki, J.Kiszel, P.Vatay, A.Blasko, B.Kovacs, M.Korner, A.Madacsy, L.Blatniczky, L.Almassy,
Z.Szalai, C.Rajczy, K.Pozsonyi, E.Karadi, I.Fazakas, A.Hosszufalusi, N.Panczel, P.Arason, G. J.Wu, Y. L.Zhou, B.Yang, Y.Yu, C. Y.Fust, G: The HLA 8.1 ancestral haplotype is strongly linked to the C allele of -429T>C promoter polymorphism of receptor of the advanced glycation endproduct (RAGE) gene. Haplotype-independent association of the -429C allele with high hemoglobin(A1C) levels in diabetic patients. Mol. Immunol. 44, 648-655, 2007 (impact factor: 3,742)
213. Judit Laki, István Laki, Krisztina Németh, Rita Újhelyi, Olga Bede, Emőke Endreffy, Katalin
Bolbás, Kálmán Gyurkovits, Eszter Csiszér, Enikő Sólyom, Gergely Dobra, Adrienn Halász, Éva Pozsonyi, Katalin Rajczy, Zoltán Prohászka, György Fekete, George Füst: The 8.1 ancestral MHC haplotype is associated with delayed onset of colonization in cystic fibrosis. International Immunol, 18, 1585-90, 2006 (impact factor: 4,015)
214. Adrienn Bíró, Zoltán Prohászka, George Füst, Bernadett Blaskó: Determination of
complement factor H functional polymorphisms (V62I, Y402H, and E936D) using sequence-specific primer PCR and restriction fragment length polymorphisms.Mol. Dioagn Ther 10, 303-310, 2006 (impact factor: 1,390)
215 Petra Kiszel, George Füst, Mikko Hurme, Zoltán Prohászka: Associations between
Interleukin-6 genetic polymorphisms and levels of autoantibodies to 60-kDa heat-shock proteins. Human Heredity, 62, 77-83, 2006 (impact factor: 2.051)
216. Éva Katalin Tóth, Judit Kocsis, Balázs Madaras, Adrienn Bíró, Zsuzsa Pocsai, George Fust,
Bernadett Blaskó, István Karádi, Róza Ádány, Judit Laki: The 8.1 ancestral MHC haplotype is strongly associated with colorectal cancer risk. Int. J. Cancer 121, 1744- 1748, 2007 (impact factor: 4,555)
217. Visy B, Füst G, Bygum A, Bork K, Longhurst H, Bucher C, Bouillet L, Cicardi M, Farkas H.
Helicobacter pylori infection as a triggering factor of attacks in patients with hereditary angioedema. Helicobacter. 2007 Jun;12(3):251-7. (impact factor: 2,423)
218. Molvarec A, Széplaki G, Kovács M, Széplaki Z, Fazakas A, Prohászka Z, Füst G, Karádi I.
Estrogen receptor alpha (ESR1) PvuII and XbaI gene polymorphisms in ischemic stroke in a Hungarian population. Clin Chim Acta. 2007 Jul;382(1-2):100-5. (impact factor: 2,601)
219. Kiszel P, Kovács M, Szalai C, Yang Y, Pozsonyi E, Blaskó B, Laki J, Prohászka Z, Fazakas
A, Pánczél P, Hosszúfalusi N, Rajczy K, Wu YL, Chung EK, Zhou B, Blanchong CA, Vatay A, Yu CY, Füst G. Frequency of carriers of 8.1 ancestral haplotype and its fragments in two Caucasian populations. Immunol Invest. 2007;36(3):307-19. (impact factor: 1,529)
220. Szabó A, Laki J, Madsen HO, Dósa E, Prohászka Z, Rugonfalvi-Kiss S, Kókai M, Acsádi G,
Karádi I, Entz L, Selmeci L, Romics L, Füst G, Garred P, Cervenak L. Early rise in serum VEGF and PDGF levels predisposes patients with a normal MBL2 genotype to restenosis after eversion endarterectomy. Stroke. 2007 Aug;38(8):2247-53. (impact factor:6,296)
221. Farkas H, Jakab L, Temesszentandrási G, Visy B, Harmat G, Füst G, Széplaki G, Fekete B,
Karádi I, Varga L. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol. 2007 Oct;120(4):941-7 (impact factor:8,115)
222. Széplaki G, Varga L, Laki J, Dósa E, Rugonfalvi-Kiss S, Madsen HO, Prohászka Z, Kocsis
A, Gál P, Szabó A, Acsády G, Karádi I, Selmeci L, Garred P, Füst G, Entz L. Low C1- inhibitor levels predict early restenosis after eversion carotid endarterectomy. Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2756-62. (impact factor:7,221)
223. Jakab L, Laki J, Sallai K, Temesszentandrási G, Pozsonyi T, Kalabay L, Varga L, Gombos
T, Blaskó B, Bíró A, Madsen HO, Radics J, Gergely P, Füst G, Czirják L, Garred P, Fekete B. Association between early onset and organ manifestations of systemic lupus erythematosus (SLE) and a down-regulating promoter polymorphism in the MBL2 gene. Clin Immunol. 2007 Dec;125(3):230-6. (impact factor:3,551)
224. Szegedi R, Széplaki G, Varga L, Prohászka Z, Széplaki Z, Karádi I, Füst G, Farkas H.
Long-term danazol prophylaxis does not lead to increased carotid intima-media thickness in hereditary angioedema patients.Atherosclerosis. 2008 May;198(1):184-91. . (impact factor:4,287)
225. Blaskó B, Kolka R, Thorbjornsdottir P, Sigurdarson ST, Sigurdsson G, Rónai Z, Sasvári-
Székely M, Bödvarsson S, Thorgeirsson G, Prohászka Z, Kovács M, Füst G, Arason GJ. Low complement C4B gene copy number predicts short-term mortality after acute myocardial infarction. Int Immunol. 2008 Jan;20(1):3 1-7 . (impact factor:3,290))
226. Varga L, Bíró A, Széplaki G, Tóth L, Horváth A, Füst G, Farkas H. Anti-cholesterol antibody
levels in hereditary angioedema. J Cell Mol Med. 2007 Nov-Dec;11(6):1377-83 (impact factor:6,807)
227. Beck Z, Prohászka Z, Füst G. Traitors of the immune system-enhancing antibodies in HIV
infection: their possible implication in HIV vaccine development. Vaccine. 2008 Jun 6;26(24):3078-85. Review. . (impact factor:3,377)
228. Széplaki G, Hirschberg K, Gombos T, Varga L, Prohászka Z, Dósa E, Acsády G, Karádi I,
Garred P, Entz L, Füst G. Early complement activation follows eversion carotid endarterectomy and correlates with the time of clamping of the carotid artery. Mol Immunol. 2008 Jun;45(11):3289-94. . (impact factor:3,742)
229. Kádár K, Kovács M, Karádi I, Melegh B, Pocsai Z, Mikala G, Tordai A, Szilágyi A, Adány R,
Füst G, Várkonyi J. Polymorphisms of TNF-alpha and LT-alpha genes in multiple myeloma. Leuk Res. 2008 Oct;32(10):1499-504. . (impact factor:2,561)
230 Varga L, Széplaki G, Laki J, Kocsis A, Kristóf K, Gál P, Bajtay Z, Wieslander J, Daha MR,
Garred P, Madsen HO, Füst G, Farkas H. Depressed activation of the lectin pathway of complement in hereditary angioedema. Clin Exp Immunol. 2008 Jul;153(1):68-74. . (impact factor:2,599)
231 Kis Z, Burian K, Treso B, Acs K, Prohaszka Z, Fust G, Gonczol E, Endresz V. Inflammatory-
and immune responses in relation to bacterial replication in mice following re-infections with Chlamydophila pneumoniae. Inflamm Res. 2008 Jun;57(6):287-95. . (impact factor:1,504)
232. Wagenaar-Bos IG, Drouet C, Aygören-Pursun E, Bork K, Bucher C, Bygum A, Farkas, H,
Fust G, Gregorek H, Hack CE, Hickey A, Joller-Jemelka HI, Kapusta M, Kreuz W,
Longhurst H, Lopez-Trascasa M, Madalinski K, Naskalski J, Nieuwenhuys E, Ponard, D, Truedsson L, Varga L, Nielsen EW, Wagner E, Zingale L, Cicardi M, van Ham SM. Functional C1-Inhibitor diagnostics in hereditary angioedema: Assay evaluation and recommendations. J Immunol Methods. 2008 Jul 22. [Epub ahead of print] . (impact factor:1,947)
233. Kaur G, Kumar N, Szilagyi A, Blasko B, Fust G, Rajczy K, Pozsonyi E, osso A, Petranyi G,
Tandon N, Mehra N. Autoimmune-associated HLA-B8-DR3 haplotypes in Asian Indians are unique in C4 complement gene copy numbers and HSP-2 1267A/G.Hum Immunol. 2008 Jul 24. [Epub ahead of print] . (impact factor:2,901)
234. Arason GJ, Kramer J, Blaskó B, Kolka R, Thorbjornsdottir P, Einarsdóttir K, Sigfúsdóttir A,
Sigurdarson ST, Sigurdsson G, Rónai Z, Prohászka Z, Sasvári-Székely M, Bödvarsson S, Thorgeirsson G, Füst G. Smoking and a complement gene polymorphism interact in promoting cardiovascular disease morbidity and mortality. Clin exp Immunol. 149, 132-8, 2007 . (impact factor:2,599)
235. Szilágyi A, Fust G. Diseases associated with the low copy number of the C4B gene
encoding C4, the fourth component of complement. Cytogenet Genome Res.2008;123(1- 4):118-30. (impact factor:1,729)
236 Széplaki G, Varga L, Szépvölgyi A, Simon K, Blaskó B, Nagy E, Karádi I, Füst G, Farkas H.
Acquired angioedema associated with primary antiphospholipid syndrome in a patient with antithrombin III deficiency. Int Arch Allergy Immunol.2008;146(2):164-8. (impact factor:2,542)
237. Bowen T, Cicardi M, Bork K, Zuraw B, Frank M, Ritchie B, Farkas H, Varga L, Zingale LC,
Binkley K, Wagner E, Adomaitis P, Brosz K, Burnham J, Warrington R, Kalicinsky C, Mace S, McCusker C, Schellenberg R, Celeste L, Hebert J, Valentine K, Poon MC, Serushago B, Neurath D, Yang W, Lacuesta G, Issekutz A, Hamed A, Kamra P, Dean J, Kanani A, Stark D, Rivard GE, Leith E, Tsai E, Waserman S, Keith PK, Page D, Marchesin S, Longhurst HJ, Kreuz W, Rusicke E, Martinez-Saguer I, Aygören-Pürsün E, Harmat G, Füst G, Li H, Bouillet L, Caballero T, Moldovan D, Späth PJ, Smith-Foltz S, Nagy I, Nielsen EW, Bucher C, Nordenfelt P, Xiang ZY. Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol. 2008 Jan;100(1 Suppl 2):S30-40. Review (impact factor: )
238. Füst G. Genetic and immune correlates of the HIV infection and vaccine-induced immunity.
Foreword. Vaccine. 2008 Jun 6;26(24):2949-50. (impact factor:3,616)
239. Széplaki G, Szegedi R, Hirschberg K, Gombos T, Varga L, Karádi I, Entz L, Széplaki Z,
Garred P, Prohászka Z, Füst G. Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes. Atherosclerosis.2009 May;204(1):315-20. (impact factor:4,522)
240. Santos PS, Füst G, Prohászka Z, Volz A, Horton R, Miretti M, Yu CY, Beck S, Uchanska-
Ziegler B, Ziegler A. Association of smoking behavior with an odorant receptor allele telomeric to the human major histocompatibility complex. Genet Test. 2008 Dec;12(4):481-6 (impact factor:1,170)
241. Pozsonyi E, György B, Berki T, Bánlaki Z, Buzás E, Rajczy K, Hossó A, Prohászka Z,
Szilágyi A, Cervenak L, Füst G. HLA-association of serum levels of natural antibodies. Mol Immunol. 2009 Apr;46(7):1416-23. (impact factor:3,202)
242. Hirschberg K, Gombos T, Dósa E, Somorjai A, Szilágyi A, Szabó G, Füst G, Entz L.
Association between estrogen receptor alpha gene polymorphisms and early restenosis after eversion carotid endarterectomy and carotid stenting. Atherosclerosis. 2009 Sep;206(1):186-92. (impact factor: 4,522)
243. Aladzsity I, Kovács M, Semsei A, Falus A, Szilágyi A, Karádi I, Varga G, Füst G, Várkonyi J.
Comparative analysis of IL6 promoter and receptor polymorphisms in myelodysplasia and multiple myeloma. Leuk Res. 2009 Nov;33(11):1570-3 (impact factor:2,358)
244. Széplaki G, Varga L, Füst G, Prohászka Z. Role of complement in the pathomechanism of
atherosclerotic vascular diseases. Mol Immunol. 2009 Sep;46(14):2784-93. (impact factor: 3,202)
245. Blaskó B, Bánlaki Z, Gyapay G, Pozsonyi E, Sasvári-Székely M, Rajczy K, Füst G, Szilágyi
A. Linkage analysis of the C4A/C4B copy number variation and polymorphisms of the adjacent steroid 21-hydroxylase gene in a healthy population. Mol Immunol. 2009 Aug;46(13):2623-9 (impact factor: 3,202)
246. Herczenik E, Varga Z, Eros D, Makó V, Oroszlán M, Rugonfalvi-Kiss S, Romics L, Füst G,
Kéri G, Orfi L, Cervenak L. Protein kinase inhibitor-induced endothelial cell cytotoxicity and its prediction based on calculated molecular descriptors. J Recept Signal Transduct Res. 2009;29(2):75-83 (impact factor:)
247. Kocsis J, Madaras B, Tóth EK, Füst G, Prohászka Z. Serum level of soluble 70-kD heat
shock protein is associated with high mortality in patients with colorectal cancer without distant metastasis. Cell Stress Chaperones. 2010 Mar;15(2):143-51 (impact factor:2,167)
248. Beck Z, Balogh A, Kis A, Izsépi E, Cervenak L, László G, Bíró A, Liliom K, Mocsár G,
Vámosi G, Füst G, Matko J. New cholesterol-specific antibodies remodel HIV-1 target cells' surface and inhibit their in vitro virus production. J Lipid Res. 2010 Feb;51(2):286- 96. (impact factor:4,917)
249. Safrany E, Hobor R, Jakab L, Tarr T, Csongei V, Jaromi L, Sipeky C, Valasek A, Zeher M,
Fust G, Czirjak L, Melegh B. Interleukin-23 receptor gene variants in Hungarian systemic lupus erythematosus patients. Inflamm Res. 2010 Feb;59(2):159-64. (impact factor:1,586)
250. Kelemen Z, Moldovan D, Mihály E, Visy B, Széplaki G, Csuka D, Füst G, Farkas H, Varga L.
Baseline level of functional C1-inhibitor correlates with disease severity scores in hereditary angioedema. Clin Immunol. 2010 Mar;134(3):354-8. (impact factor:3,863)
251. Farkas H, Czaller I, Csuka D, Vas A, Valentin S, Varga L, Széplaki G, Jakab L, Füst G,
Prohászka Z, Harmat G, Visy B, Karádi I. The effect of long-term danazol prophylaxis on liver function in hereditary angioedema-a longitudinal study. Eur J Clin Pharmacol. 2010 Apr;66(4):419-26. (impact factor:2,743)
252. Mészáros T, Füst G, Farkas H, Jakab L, Temesszentandrási G, Nagy G, Kiss E, Gergely P,
Zeher M, Griger Z, Czirják L, Hóbor R, Haris A, Polner K, Varga L. C1-inhibitor autoantibodies in SLE. Lupus. 2010 Apr;19(5):634-8. (impact factor:2,586)
253. Varbiro S, Biro A, Cervenak J, Cervenak L, Singh M, Banhidy F, Sebestyen A, Füst G,
Prohászka Z. Human anti-60 kD heat shock protein autoantibodies are characterized by basic features of natural autoantibodies. Acta Physiol Hung. 2010 Mar;97(1):1-10. (impact factor:)
254. Barbai VH, Ujhelyi E, Szlávik J, Vietorisz I, Varga L, Fey E, Füst G, Bánhegyi D. Changes in
the levels of some acute-phase proteins in human immunodeficiency virus-1 infected patients, following interleukin-2 treatment. Clin Exp Immunol. 2010 Jul 1;161(1):134-41. (impact factor:3,009)
255. Szilágyi A, Bánlaki Z, Pozsonyi E, Yunis EJ, Awdeh ZL, Hossó A, Rajczy K, Larsen CE, Fici
DA, Alper CA, Füst G. Frequent occurrence of conserved extended haplotypes (CEHs) in two Caucasian populations. Mol Immunol. 2010 Jun;47(10):1899-904 (impact factor: 3,202)
256. Madách K, Aladzsity I, Szilágyi A, Fust G, Gál J, Pénzes I, Prohászka Z. 4G/5G
polymorphism of PAI-1 gene is associated with multiple organ dysfunction and septic shock in pneumonia induced severe sepsis: prospective, observational, genetic study. Crit Care. 2010;14(2):R79. Epub 2010 Apr 29. (impact factor:6,373)
257. Czaller I, Visy B, Csuka D, Füst G, Tóth F, Farkas H. The natural history of hereditary
angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. Eur J Obstet Gynecol Reprod Biol. 2010 Sep;152(1):44-9 (impact factor:1,582)
258. Kelemen Z, Visy B, Csuka D, Czaller I, Füst G, Farkas H. Abdominal symptoms of
hereditary angioedema and early weaning. Eur J Clin Nutr. 2010 Sep;64(9):1025-7 (impact factor:3,072)
259. Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, Aygoeren-Pürsün E, Craig
T, Binkley K, Hebert J, Ritchie B, Bouillet L, Betschel S, Cogar D, Dean J, Devaraj R, Hamed A, Kamra P, Keith PK, Lacuesta G, Leith E, Lyons H, Mace S, Mako B, Neurath D, Poon MC, Rivard GE, Schellenberg R, Rowan D, Rowe A, Stark D, Sur S, Tsai E, Warrington R, Waserman S, Ameratunga R, Bernstein J, Björkander J, Brosz K, Brosz J, Bygum A, Caballero T, Frank M, Fust G, Harmat G, Kanani A, Kreuz W, Levi M, Li H, Martinez-Saguer I, Moldovan D, Nagy I, Nielsen EW, Nordenfelt P, Reshef A, Rusicke E, Smith-Foltz S, Späth P, Varga L, Xiang ZY. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):24. (impact factor:)
260. Kocsis J, Mészáros T, Madaras B, Tóth EK, Kamondi S, Gál P, Varga L, Prohászka Z, Füst
G. High levels of acute phase proteins and soluble 70 kDa heat shock proteins are independent and additive risk factors for mortality in colorectal cancer. Cell Stress Chaperones. 2010 Aug 22. [Epub ahead of print] (impact factor: 2,167)
261. Csuka D, Molvarec A, Derzsy Z, Varga L, Füst G, Rigó J Jr, Prohászka Z. Functional
analysis of the mannose-binding lectin complement pathway in normal pregnancy and preeclampsia. J Reprod Immunol. 2010 Oct 15. [Epub ahead of print] (impact factor:2,519)
262. Füst G, Farkas H, Csuka D, Varga L, Bork K. Long-term efficacy of danazol treatment in
hereditary angioedema. Eur J Clin Invest. 2010 Oct 18. [Epub ahead of print] (impact factor:2,643)
SUGGESTED RWANDA PACKING LIST CARRY-ON BAG(s) □ Camera(s) with charger(s), extra battery(ies), and all SD and/or flash cards □ Digital video camcorder (optional) □ Neck holder for passport, etc □ Cell phone w/SIM card/charging chord □ Pocket size notebook □ Yellow □ Extra AAA batteries □ Sunglasses □ Grounding Adaptor Plug D and the European Style Adaptor Plug Adap
I N R E C E N T Y E A R S , P H A R M A C E U T I C A L D R U G S H AV Ebecome implicated in global politics as never before. Inequitabledrug prices, persisting di√erences in national regulatory approaches,and debates over how to define safety and e≈cacy for diverse patientpopulations around the globe now attract an unprecedented degreeof attention. The political, financial, and human health